Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

Eligibility Requirements:

  • Diagnosis of amnestic Mild Cognitive Impairment (aMCI) or early Alzheimer’s
  • Currently resides in the greater New York City or Rockland County areas
  • Has at least a high school diploma/12 years of education
  • Does not have a history of brain tumor, MRI evidence of serious neurological disorders such as epilepsy, ALS, Parkinson’s disease, MS, Tourette syndrome, or history of significant cardiovascular or cerebrovascular disease.

About the Study:

The TRAP-AD study is investigating an experimental treatment device for amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer’s disease in a randomized clinical trial of 8 weeks of transcranial

photobiomodulation (tPBM) or sham (placebo) treatment. The t-PBM treatment stimulates

certain parts of the brain that are thought to be affected in memory impairment and may improve cognition in adults with aMCI and early Alzheimer’s.


The TRAP-AD study will test whether an experimental treatment device that uses near-infrared light therapy will lead to improvement in cognition in adults with amnestic Mild Cognitive Impairment (aMCI) and early Alzheimer’s.

What is Involved:

The tPBM device uses near-infrared light to stimulate areas of the brain near the forehead; it is a non-pharmacologic investigational treatment. Participants will first complete an assessment of medical history and memory to verify eligibility, undergo medical imaging procedures, and will then be randomized to either t-PBM or sham (placebo) treatment for 8 weeks (3 sessions per week, approximately 30-minute visit time per session). Following treatment, cognitive symptoms will be assessed two additional times to detect any improvement.

Participants will be compensated for their time.

65 to 85
5-7 months
Approximately 31
Study Type:
Prevention Studies; Studies for People with Memory Impairment